Show simple item record

dc.contributor.authorWeeding, Emma
dc.contributor.authorFava, Andrea
dc.contributor.authorMagder, Laurence
dc.contributor.authorGoldman, Daniel
dc.contributor.authorPetri, Michelle
dc.date.accessioned2022-05-09T15:30:26Z
dc.date.available2022-05-09T15:30:26Z
dc.date.issued2022-04-09
dc.identifier.urihttp://hdl.handle.net/10713/18800
dc.description.abstractWe conducted a single-centre study of patients diagnosed with their first episode of biopsy-proven class III, IV, and/or V LN (n=37). For each patient, eGFR trajectory was graphed over 5 years following renal biopsy. Participants were divided into those with progressive eGFR loss (eGFR slope <-5 mL/min/1.73 m2/year) versus those with stable eGFR. Participant demographics, renal biopsy features and response status at 1 year (urine protein to creatinine ratio <500 mg/g) were compared between eGFR trajectory groups.en_US
dc.description.urihttps://doi.org/10.1136/lupus-2022-000684en_US
dc.language.isoenen_US
dc.publisherBMJ Publishing Groupen_US
dc.relation.ispartofLupus Science & Medicineen_US
dc.rights© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.en_US
dc.subjectLupus Nephritisen_US
dc.subjectOutcome Assessment, Health Careen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.titleOne-third of patients with lupus nephritis classified as complete responders continue to accrue progressive renal damage despite resolution of proteinuria.en_US
dc.typeArticleen_US
dc.identifier.doi10.1136/lupus-2022-000684
dc.identifier.pmid35512816
dc.source.journaltitleLupus science & medicine
dc.source.volume9
dc.source.issue1
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record